Discovery, mechanisms of action and combination therapy of artemisinin

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 8, 2009, Pages 999-1013

  Cui, Liwang ^a   Su, Xin Zhuan ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antimalarial drugs; Artemisinin based combinatory therapy; Drug resistant malaria; Plasmodium

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISIA ANNUA EXTRACT; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ARTESUNATE PLUS FANSIDAR; ARTESUNATE PLUS MEFLOQUINE; ARTESUNATE PLUS PYRONARIDINE; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; FREE RADICAL; HEME; MEFLOQUINE; NAPHTHOQUINONE; PROTEIN; PYRONARIDINE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ARTEMISIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EMBRYOTOXICITY; HISTORY OF MEDICINE; HUMAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MITOCHONDRION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POLYMERIZATION; REVIEW; UNSPECIFIED SIDE EFFECT;

ADULT; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC;

EID: 70350616263     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.68     Document Type: Review

References (199)

1. Roberts L, Enserink M. Malaria. Did they really say eradication? Science 318, 1544-1545 (2007). (Pubitemid 350233641)
2. Olliaro P. Drug resistance hampers our capacity to roll back malaria. Clin. Infect. Dis. 41, S247-S257 (2005).
3. Bosman A, Mendis KN. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am. J. Trop. Med. Hyg. 77, 193-197 (2007).
4. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 228, 1049-1055 (1985).
5. Li Y, Wu YL. How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives? Med. Trop. (Mars.) 58, S9-S12 (1998). (Pubitemid 128707810)
6. Li Y, Wu YL. An over four millennium story behind qinghaosu (artemisinin) - a fantastic antimalarial drug from a traditional Chinese herb. Curr. Med. Chem. 10, 2197-2230 (2003). (Pubitemid 37236383)
7. Kuhn T, Wang Y. Artemisinin - an innovative cornerstone for anti-malaria therapy. Prog. Drug Res. 66(383), 385-422 (2008).
8. Hsu E. Reflections on the 'discovery' of the antimalarial qinghao. Br. J. Clin. Pharmacol. 61, 666-670 (2006).
9. Zhang J-F. A detailed chronological record of Project 523 and the discovery and development of qinghaosu (artemisinin). Yangcheng Evening News Publishing Company, China, 193 (2005).
10. Hsu E. The history of qing hao in the Chinese materia medica. Trans. R. Soc. Trop. Med. Hyg. 100, 505-508 (2006).
11. Rath K, Taxis K, Walz G, Gleiter CH, Li SM, Heide L. Pharmacokinetic study of artemisinin after oral intake of a traditional preparation of Artemisia annua L. (annual wormwood). Am. J. Trop. Med. Hyg. 70, 128-132 (2004).
12. Mueller MS, Runyambo N, Wagner I, Borrmann S, Dietz K, Heide L. Randomized controlled trial of a traditional preparation of Artemisia annua L. (annual wormwood) in the treatment of malaria. Trans. R. Soc. Trop. Med. Hyg. 98, 318-321 (2004).
13. Blanke CH, Naisabha GB, Balema MB, Mbaruku GM, Heide L, Muller MS. Herba Artemisiae annuae tea preparation compared to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in adults: a randomized double-blind clinical trial. Trop. Doc. 38, 113-116 (2008).
14. Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. Trends Pharmacol. Sci. 29, 520-527 (2008).
15. Zeng Q, Qiu F, Yuan L. Production of artemisinin by genetically-modified microbes. Biotechnol. Lett. 30, 581-592 (2008).
16. Skinner TS, Manning LS, Johnston WA, Davis TM. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int. J. Parasitol. 26, 519-525 (1996).
17. Kumar N, Zheng H. Stage-specific gametocytocidal effect in vitro of the antimalaria drug qinghaosu on Plasmodium falciparum. Parasitol. Res. 76, 214-218 (1990). (Pubitemid 20116097)
18. Chen PQ, Li GQ, Guo XB. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinine. Chin. Med. J. 74, 107, 709-711 (1994).
19. White NJ. Qinghaosu (artemisinin): the price of success. Science 320, 330-334 (2008).
20. Woodrow CJ, Haynes RK, Krishna S. Artemisinins. Postgrad. Med. J. 81, 71-78 (2005).
21. Pasvol G. The treatment of complicated and severe malaria. Br. Med. Bull. 75-76, 29-47 (2005).
22. McIntosh HM, Olliaro P. Artemisinin derivatives for treating severe malaria. Cochrane Database Syst. Rev. (2), CD000527 (2000).
23. Praygod G, de Frey A, Eisenhut M. Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review. Malaria J. 7, 210 (2008).
24. Group SEAQAMT. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366, 717-725 (2005).
25. Karunajeewa HA, Manning L, Mueller I, Ilett KF, Davis TM. Rectal administration of artemisinin derivatives for the treatment of malaria. JAMA 297, 2381-2390 (2007).
26. Gomes M, Ribeiro I, Warsame M, Karunajeewa H, Petzold M. Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies. BMC Infect. Dis. 8, 39 (2008) .
27. Gomes MF, Faiz MA, Gyapong JO et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 373, 557-566 (2009).
28. Lee IS, Hufford CD. Metabolism of antimalarial sesquiterpene lactones. Pharmacol. Ther. 48, 345-355 (1990).
29. Grace JM, Aguilar AJ, Trotman KM, Peggins JO, Brewer TG. Metabolism of β-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab. Dispos. 26, 313-317 (1998).
30. Ilett KF, Ethell BT, Maggs JL et al. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab. Dispos. 30, 1005-1012 (2002).
31. Svensson US, Maki-Jouppila M, Hoffmann KJ, Ashton M. Characterisation of the human liver in vitro metabolic pattern of artemisinin and auto-induction in the rat by use of nonlinear mixed effects modelling. Biopharm. Drug Dispos. 24, 71-85 (2003). (Pubitemid 36335927)
32. Li QG, Peggins JO, Fleckenstein LL, Masonic K, Heiffer MH, Brewer TG. The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. J. Pharm. Pharmacol. 50, 173-182 (1998). (Pubitemid 28102574)
33. Olliaro PL, Nair NK, Sathasivam K, Mansor SM, Navaratnam V. Pharmacokinetics of artesunate after single oral administration to rats. BMC Pharmacol. 1, 12 (2001). (Pubitemid 38729234)
34. Ashton M, Hai TN, Sy ND et al. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab. Dispos. 26, 25-27 (1998). (Pubitemid 28071320)
35. Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M. Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob. Agents Chemother. 46, 1026-1031 (2002).
36. Simonsson US, Jansson B, Hai TN, Huong DX, Tybring G, Ashton M. Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin. Pharmacol. Ther. 74, 32-43 (2003). (Pubitemid 36776174)
37. Asimus S, Elsherbiny D, Hai TN et al. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fund. Clin. Pharmacol. 21, 307-316 (2007). (Pubitemid 46800472)
38. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77(Suppl. 6), 181-192 (2007).
39. Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol. Rev. 60, 301-315 (1996). (Pubitemid 26171692)
40. Menard D, Matsika-Claquin MD, Djalle D et al. Association of failures of seven-day courses of artesunate in a non-immune population in Bangui, Central African Republic with decreased sensitivity of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 73, 616-621 (2005). (Pubitemid 41324271)
41. Ashley EA, White NJ. Artemisinin-based combinations. Curr. Opin. Infect. Dis. 18, 531-536 (2005).
42. Davis TM, Karunajeewa HA, Ilett KF. Artemisinin-based combination therapies for uncomplicated malaria. Med. J. Aust. 182, 181-185 (2005).
43. White N. Antimalarial drug resistance and combination chemotherapy. Phil. Trans. R. Soc. Lond. 354, 739-749 (1999).
44. Kremsner PG, Krishna S. Antimalarial combinations. Lancet 364, 285-294 (2004).
45. Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Exp. Opin. Pharmacother. 8, 75-94 (2007). (Pubitemid 46070831)
46. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 27, 25-61 (2004).
47. Ashley EA, Lwin KM, McGready R et al. An open label randomized comparison of mefloquine - artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Trop. Med. Int. Health 11, 1653-1660 (2006).
48. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperaquine: a resurgent antimalarial drug. Drugs 65, 75-87 (2005).
49. Ramharter M, Kurth F, Schreier AC et al. Fixed-dose pyronaridine- artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J. Infect. Dis. 198, 911-919 (2008).
50. Karunajeewa HA, Mueller I, Senn M et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359, 2545-2557 (2008).
51. Thwing JI, Odero CO, Odhiambo FO et al. In-vivo efficacy of amodiaquine- artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. Trop. Med. Int. Health 14, 294-300 (2009).
52. Phan GT, de Vries PJ, Tran BQ et al. Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Trop. Med. Int. Health 7, 858-864 (2002).
53. Hamedi Y, Safa O, Zare S, Tan-ariya P, Kojima S, Looareesuwan S. Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand. Southeast Asian J. Trop. Med. Public Health 35, 570-574 (2004).
54. Nguyen MH, Davis TM, Cox-Singh J et al. Treatment of uncomplicated falciparum malaria in southern Vietnam: can chloroquine or sulfadoxine- pyrimethamine be reintroduced in combination with artesunate? Clin. Infect. Dis. 37, 1461-1466 (2003). (Pubitemid 37494673)
55. Mockenhaupt FP. Mefloquine resistance in Plasmodium falciparum. Parasitol. Today 11, 248-253 (1995).
56. Yang H, Liu D, Huang K et al. Assay of sensitivity of Plasmodium falciparum to chloroquine, amodiaquine, piperaquine, mefloquine and quinine in Yunnan province. Chin. J. Parasitol. Parasitic Dis. 17, 43-45 (1999).
57. Martensson A, Stromberg J, Sisowath C et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin. Infect. Dis. 41, 1079-1086 (2005). (Pubitemid 41429468)
58. Durrani N, Leslie T, Rahim S, Graham K, Ahmad F, Rowland M. Efficacy of combination therapy with artesunate plus amodiaquine compared to monotherapy with chloroquine, amodiaquine or sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum in Afghanistan. Trop. Med. Int. Health 10, 521-529 (2005).
59. Brockman A, Price RN, van Vugt M et al. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans. R. Soc. Trop. Med. Hyg. 94, 537-544 (2000).
60. Nosten F, van Vugt M, Price R et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356, 297-302 (2000). (Pubitemid 30459588)
61. Olliaro PL, Taylor WR. Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: a review. J. Postgrad. Med. 50, 40-44 (2004).
62. Gordi T, Lepist EI. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol. Lett. 147, 99-107 (2004). (Pubitemid 38130178)
63. Brewer TG, Genovese RF, Newman DB, Li Q. Factors relating to neurotoxicity of artemisinin antimalarial drugs 'listening to arteether'. Med. Trop. (Mars.) 58(Suppl. 3), 22-27 (1998).
64. Nontprasert A, Pukrittayakamee S, Dondorp AM, Clemens R, Looareesuwan S, White NJ. Neuropathologic toxicity of artemisinin derivatives in a mouse model. Am. J. Trop. Med. Hyg. 67, 423-429 (2002). (Pubitemid 35303868)
65. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans. R. Soc. Trop. Med. Hyg. 98, 261-267 (2004).
66. McCall MB, Beynon AJ, Mylanus EA, van der Ven AJ, Sauerwein RW. No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria. Trans. R. Soc. Trop. Med. Hyg. 100, 1098-1104 (2006).
67. Hutagalung R, Htoo H, Nwee P et al. A case-control auditory evaluation of patients treated with artemether-lumefantrine. Am. J. Trop. Med. Hyg. 74, 211-214 (2006).
68. Toovey S. Are currently deployed artemisinins neurotoxic? Toxicol. Lett. 166, 95-104 (2006). (Pubitemid 44291960)
69. White TE, Bushdid PB, Ritter S, Laffan SB, Clark RL. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Defects Res. 77, 413-429 (2006).
70. Clark RL, Arima A, Makori N et al. Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res. 83, 418-434 (2008).
71. Clark RL. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod. Toxicol. (2009) (Epub ahead of print).
72. Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety of artemisinins during pregnancy: a pressing question. Malaria J. 6, 15 (2007). (Pubitemid 46321435)
73. Olliaro PL, Haynes RK, Meunier B, Yuthavong Y. Possible modes of action of the artemisinin-type compounds. Trends Parasitol. 17, 122-126 (2001). (Pubitemid 32422178)
74. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 32, 1655-1660 (2002).
75. Krishna S, Uhlemann AC, Haynes RK. Artemisinins: mechanisms of action and potential for resistance. Drug Resist. Updat. 7, 233-244 (2004). (Pubitemid 39469096)
76. Krishna S, Woodrow CJ, Staines HM, Haynes RK, Mercereau-Puijalon O. Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol. Med. 12, 200-205 (2006). (Pubitemid 43728412)
77. Haynes RK, Krishna S. Artemisinins: activities and actions. Microbes Infect. 6, 1339-1346 (2004).
78. Zhang F, Gosser DK Jr, Meshnick SR. Hemin-catalyzed decomposition of artemisinin (qinghaosu). Biochem. Pharmacol. 43, 1805-1809 (1992).
79. Meshnick SR, Jefford CW, Posner GH, Avery MA, Peters W. Second-generation antimalarial endoperoxides. Parasitol. Today 12, 79-82 (1996).
80. Ploypradith P. Development of artemisinin and its structurally simplified trioxane derivatives as antimalarial drugs. Acta Trop. 89, 329-342 (2004). (Pubitemid 38117069)
81. Krungkrai SR, Yuthavong Y. The antimalarial action on Plasmodium falciparum of qinghaosu and artesunate in combination with agents which modulate oxidant stress. Trans. R. Soc. Trop. Med. Hyg. 81, 710-714 (1987). (Pubitemid 18070979)
82. Ittarat W, Sreepian A, Srisarin A, Pathepchotivong K. Effect of dihydroartemisinin on the antioxidant capacity of P. falciparum-infected erythrocytes. Southeast Asian J. Trop. Med. Public Health 34, 744-750 (2003).
83. Wu WM, Wu Y, Wu YL et al. Unified mechanistic framework for the Fe(II)- induced cleavage of qinghaosu and derivatives/analogues. The first spin-trapping evidence for the previously postulated secondary C-4 radical. J. Am. Chem. Soc. 120, 3316-3325 (1998).
84. Stocks PA, Bray PG, Barton VE et al. Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs. Angew. Chem. 46, 6278-6283 (2007).
85. Meshnick SR, Thomas A, Ranz A, Xu CM, Pan HZ. Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. Mol. Biochem. Parasitol. 49, 181-189 (1991).
86. Paitayatat S, Tarnchompoo B, Thebtaranonth Y, Yuthavong Y. Correlation of antimalarial activity of artemisinin derivatives with binding affinity with ferroprotoporphyrin IX. J. Med. Chem. 40, 633-638 (1997). (Pubitemid 27102568)
87. Meshnick SR, Yang YZ, Lima V, Kuypers F, Kamchonwongpaisan S, Yuthavong Y. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob. Agents Chemother. 37, 1108-1114 (1993). (Pubitemid 23141328)
88. Eckstein-Ludwig U, Webb RJ, Van Goethem ID et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424, 957-961 (2003). (Pubitemid 37051688)
89. Pradines B, Rolain JM, Ramiandrasoa F et al. Iron chelators as antimalarial agents: in vitro activity of dicatecholate against Plasmodium falciparum. J. Antimicrob. Chemother. 50, 177-187 (2002). (Pubitemid 34918846)
90. Haynes RK, Ho WY, Chan HW et al. Highly antimalaria-active artemisinin derivatives: biological activity does not correlate with chemical reactivity. Angew. Chem. 43, 1381-1385 (2004).
91. +-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins: the unlikelihood of C-centered radicals as bioactive intermediates. ChemMedChem 2, 1480-1497 (2007).
92. Looareesuwan S, Wilairatana P, Vannaphan S et al. Co-administration of desferrioxamine B with artesunate in malaria: an assessment of safety and tolerance. Ann. Trop. Med. Parasitol. 90, 551-554 (1996). (Pubitemid 26345684)
93. Jones-Brando L, D'Angelo J, Posner GH, Yolken R. In vitro inhibition of Toxoplasma gondii by four new derivatives of artemisinin. Antimicrob. Agents Chemother. 50, 4206-4208 (2006).
94. Kumar S, Gupta AK, Pal Y, Dwivedi SK. In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys. J. Vet. Med. Sci. 65, 1171-1177 (2003). (Pubitemid 41380039)
95. Mercer AE. The role of bioactivation in the pharmacology and toxicology of the artemisinin-based antimalarials. Curr. Opin. Drug Discov. Devel. 12, 125-132 (2009).
96. Wang D, Wu Y. A possible antimalarial action mode of qinghaosu (artemisinin) series compounds. Alkylation of reduced glutathione by C-centered primary radicals produced from antimalarial compound qinghaosu and 12-(2,4-dimethyoxyphenyl)-12- deoxoqinghaosu. Chem. Commun. 2193-2194 (2000).
97. Scott MD, Meshnick SR, Williams RA et al. Qinghaosu-mediated oxidation in normal and abnormal erythrocytes. J. Lab. Clin. Med. 114, 401-406 (1989).
98. Wu Y, Liu HH. Probing the possible molecular origin of the highly selective toxicity of antimalarial peroxide qinghaosu (artemisinin). Chem. Res. Toxicol. 16, 1202-1206 (2003). (Pubitemid 37315209)
99. Hong YL, Yang YZ, Meshnick SR. The interaction of artemisinin with malarial hemozoin. Mol. Biochem. Parasitol. 63, 121-128 (1994).
100. Kannan R, Sahal D, Chauhan VS. Heme-artemisinin adducts are crucial mediators of the ability of artemisinin to inhibit heme polymerization. Chem. Biol. 9, 321-332 (2002). (Pubitemid 34253414)
101. Kannan R, Kumar K, Sahal D, Kukreti S, Chauhan VS. Reaction of artemisinin with haemoglobin: implications for antimalarial activity. Biochem. J. 385, 409-418 (2005). (Pubitemid 40165073)
102. Robert A, Benoit-Vical F, Claparols C, Meunier B. The antimalarial drug artemisinin alkylates heme in infected mice. Proc. Natl Acad. Sci. USA 102, 13676-13680 (2005). (Pubitemid 41420907)
103. Laurent SA, Loup C, Mourgues S, Robert A, Meunier B. Heme alkylation by artesunic acid and trioxaquine DU1301, two antimalarial trioxanes. Chembiochem 6, 653-658 (2005). (Pubitemid 40873766)
104. Robert A, Meunier B. Is alkylation the main mechanism of action of the antimalarial drug artemisinin? Chem. Soc. Rev. 27, 273-279 (1998). (Pubitemid 128105687)
105. Laurent SA, Robert A, Meunier B. C10-modified artemisinin derivatives: efficient heme-alkylating agents. Angew. Chem. 44, 2060-2063 (2005). (Pubitemid 40492428)
106. Loup C, Lelievre J, Benoit-Vical F, Meunier B. Trioxaquines and hemeartemisinin adducts inhibit the in vitro formation of hemozoin better than chloroquine. Antimicrob. Agents Chemother. 51, 3768-3770 (2007). (Pubitemid 47519376)
107. Pandey AV, Tekwani BL, Singh RL, Chauhan VS. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J. Biol. Chem. 274, 19383-19388 (1999).
108. Meshnick SR. Is haemozoin a target for antimalarial drugs? Ann. Trop. Med. Parasitol. 90, 367-372 (1996).
109. Haynes RK, Monti D, Taramelli D, Basilico N, Parapini S, Olliaro P. Artemisinin antimalarials do not inhibit hemozoin formation. Antimicrob. Agents Chemother. 47, 1175 (2003). (Pubitemid 36254260)
110. Wu Y. How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. Acc. Chem. Res. 35, 255-259 (2002).
111. Wu WM, Chen YL, Zhai Z, Xiao SH, Wu YL. Study on the mechanism of action of artemether against schistosomes: the identification of cysteine adducts of both carbon-centred free radicals derived from artemether. Bioorg. Med. Chem. Lett. 13, 1645-1647 (2003). (Pubitemid 36561132)
112. Asawamahasakda W, Ittarat I, Pu YM, Ziffer H, Meshnick SR. Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob. Agents Chemother. 38, 1854-1858 (1994).
113. Bhisutthibhan J, Pan XQ, Hossler PA et al. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J. Biol. Chem. 273, 16192-16198 (1998).
114. Bhisutthibhan J, Philbert MA, Fujioka H, Aikawa M, Meshnick SR. The Plasmodium falciparum translationally controlled tumor protein: subcellular localization and calcium binding. Eur. J. Cell Biol. 78, 665-670 (1999). (Pubitemid 29484125)
115. + -ATPase(PfATP6) and docking of artemisinin derivatives to PfATP6. Bioorg. Med. Chem. Lett. 15, 2994-2997 (2005).
116. Uhlemann AC, Cameron A, Eckstein- Ludwig U et al. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat. Struct. Mol. Biol. 12, 628-629 (2005). (Pubitemid 40980816)
117. Uhlemann AC, Wittlin S, Matile H, Bustamante LY, Krishna S. Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277). Antimicrob. Agents Chemother. 51, 667-672 (2007). (Pubitemid 46185288)
118. Nagamune K, Beatty WL, Sibley LD. Artemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondii. Eukaryot. Cell 6, 2147-2156 (2007). (Pubitemid 350221283)
119. Krungkrai J, Burat D, Kudan S, Krungkrai S, Prapunwattana P. Mitochondrial oxygen consumption in asexual and sexual blood stages of the human malarial parasite, Plasmodium falciparum. Southeast Asian J. Trop. Med. Public Health 30, 636-642 (1999).
120. Li W, Mo W, Shen D et al. Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet. 1, e36 (2005).
121. Inselburg J. Induction and isolation of artemisinine-resistant mutants of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 34, 417-418 (1985).
122. Hunt P, Afonso A, Creasey A et al. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol. Microbial. 65, 27-40 (2007).
123. Chawira AN, Warhurst DC, Peters W. Qinghaosu resistance in rodent malaria. Trans. R. Soc. Trop. Med. Hyg. 80(3), 477-480 (1986).
124. Walker DJ, Pitsch JL, Peng MM et al. Mechanisms of artemisinin resistance in the rodent malaria pathogen Plasmodium yoelii. Antimicrob. Agents Chemother. 44, 344-347 (2000).
125. Ferrer-Rodriguez I, Perez-Rosado J, Gervais GW, Peters W, Robinson BL, Serrano AE. Plasmodium yoelii: identification and partial characterization of an MDR1 gene in an artemisinin-resistant line. J. Parasitol. 90, 152-160 (2004). (Pubitemid 38280744)
126. Puri SK, Chandra R. Plasmodium vinckei: selection of a strain exhibiting stable resistance to arteether. Exp. Parasitol. 114, 129-132 (2006). (Pubitemid 44374510)
127. 2+ ATPase), tctp, mdr1, and cg10. Antimicrob. Agents Chemother. 50, 480-489 (2006).
128. Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol. Sci. 27, 594-601 (2006).
129. Foote SJ, Kyle DE, Martin RK et al. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 345, 255-258 (1990).
130. Hayton K, Su XZ. Genetic and biochemical aspects of drug resistance in malaria parasites. Curr. Drug Targets 4, 1-10 (2004). (Pubitemid 38404692)
131. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol. Biochem. Parasitol. 108, 13-23 (2000).
132. Sisowath C, Stromberg J, Martensson A et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J. Infect. Dis. 199, 1014-1017 (2005).
133. Sisowath C, Petersen I, Veiga MI et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J. Infect. Dis. 199, 750-757 (2009).
134. Happi CT, Gbotosho GO, Folarin OA et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 53, 888-895 (2009).
135. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403, 906-909 (2000). (Pubitemid 30130994)
136. Sidhu AB, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol. Microbiol. 57, 913-926 (2005).
137. Wilson CM, Volkman SK, Thaithong S et al. Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol. Biochem. Parasitol. 57, 151-160 (1993). (Pubitemid 23020712)
138. Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc. Natl Acad. Sci. USA 91, 1143-1147 (1994). (Pubitemid 24048525)
139. Price RN, Cassar C, Brockman A et al. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob. Agents Chemother. 43, 2943-2949 (1999).
140. Price RN, Uhlemann AC, Brockman A et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364, 438-447 (2004). (Pubitemid 39036891)
141. Pickard AL, Wongsrichanalai C, Purfield A et al. Resistance to antimalarials in southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob. Agents Chemother. 47, 2418-2423 (2003). (Pubitemid 36919439)
142. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 194, 528-535 (2006). (Pubitemid 44162666)
143. Rohrbach P, Sanchez CP, Hayton K et al. Genetic linkage of pfmdr1 with food vacuolar solute import in Plasmodium falciparum. EMBO J. 25, 3000-3011 (2006).
144. Price RN, Uhlemann AC, van Vugt M et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 42, 1570-1577 (2006).
145. Lim P, Alker AP, Khim N et al. pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malaria J. 8, 11 (2009).
146. Mu J, Ferdig MT, Feng X et al. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol. Microbiol. 49, 977-989 (2003). (Pubitemid 36981343)
147. Anderson TJ, Nair S, Qin H et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob. Agents Chemother. 49, 2180-2188 (2005). (Pubitemid 40734444)
148. Raj DK, Mu J, Jiang H et al. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J. Biol. Chem. 284, 7687-7696 (2009).
149. Jambou R, Legrand E, Niang M et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366, 1960-1963 (2005).
150. Legrand E, Volney B, Meynard JB, Mercereau-Puijalon O, Esterre P. In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob. Agents Chemother. 52, 288-298 (2008).
151. 2+)-ATPase orthologue of Plasmodium falciparum (PfATP6). Infect. Genet. Evol. 8, 340-345 (2008).
152. Cojean S, Hubert V, Le Bras J, Durand R. Resistance to dihydroartemisinin. Emerg. Infect. Dis. 12, 1798-1799 (2006).
153. Mugittu K, Genton B, Mshinda H, Beck HP. Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania. Malaria J. 5, 126 (2006). (Pubitemid 46177993)
154. Ferreira ID, Lopes D, Martinelli A, Ferreira C, do Rosario VE, Cravo P. In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance-associated mutations of Plasmodium falciparum from Sao Tome and Principe. Trop. Med. Int. Health 12, 353-362 (2007).
155. Ibrahim ML, Khim N, Adam HH, Ariey F, Duchemin JB. Polymorphism of PfATPase in Niger: detection of three new point mutations. Malaria J. 8, 28 (2009).
156. Ibrahim ML, Steenkeste N, Khim N et al. Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA-microarrays and PCR/RFLP in Niger. Malaria J. 8, 32 (2009).
157. Bacon DJ, McCollum AM, Griffing SM et al. Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrob. Agents Chemother. 53, 2042-2051 (2009).
158. Menegon M, Sannella AR, Majori G, Severini C. Detection of novel point mutations in the Plasmodium falciparum ATPase6 candidate gene for resistance to artemisinins. Parasitol. Int. 57, 233-235 (2008).
159. Zhang G, Guan Y, Zheng B, Wu S, Tang L. No PfATPase6 S769N mutation found in Plasmodium falciparum isolates from China. Malaria J. 7, 122 (2008). (Pubitemid 352001285)
160. Fidock DA, Eastman RT, Ward SA, Meshnick SR. Recent highlights in antimalarial drug resistance and chemotherapy research. Trends Parasitol. 24, 537-544 (2008).
161. Luxemburger C, Brockman A, Silamut K et al. Two patients with falciparum malaria and poor in vivo responses to artesunate. Trans. R. Soc. Trop. Med. Hyg. 92, 668-669 (1998).
162. Gogtay NJ, Kadam VS, Karnad DR, Kanbur A, Kamtekar KD, Kshirsagar NA. Probable resistance to parenteral artemether in Plasmodium falciparum: case reports from Mumbai (Bombay), India. Ann. Trop. Med. Parasitol. 94, 519-520 (2000).
163. Sahr F, Willoughby VR, Gbakima AA, Bockarie MJ. Apparent drug failure following artesunate treatment of Plasmodium falciparum malaria in Freetown, Sierra Leone: four case reports. Ann. Trop. Med. Parasitol. 95, 445-449 (2001). (Pubitemid 32730480)
164. Oduola AM, Sowunmi A, Milhous WK et al. Innate resistance to new antimalarial drugs in Plasmodium falciparum from Nigeria. Trans. R. Soc. Trop. Med. Hyg. 86, 123-126 (1992).
165. Randrianarivelojosia M, Raharimalala LA, Randrianasolo L et al. Madagascan isolates of Plasmodium falciparum showing low sensitivity to artemether in vitro. Ann. Trop. Med. Parasitol. 95, 237-243 (2001). (Pubitemid 32521407)
166. Yang H, Liu D, Yang Y et al. Changes in susceptibility of Plasmodium falciparum to artesunate in vitro in Yunnan Province, China. Trans. R. Soc. Trop. Med. Hyg. 97, 226-228 (2003).
167. Denis MB, Tsuyuoka R, Lim P et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop. Med. Int. Health 11, 1800-1807 (2006).
168. Denis MB, Tsuyuoka R, Poravuth Y et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop. Med. Int. Health 11, 1360-1366 (2006).
169. Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A, Wongsrichanalai C. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop. Med. Int. Health 11, 211-219 (2006).
170. Rogers WO, Sem R, Tero T et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malaria J. 8, 10 (2009).
171. Carrara VI, Zwang J, Ashley EA et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS ONE, 4, e4551 (2009).
172. Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg. Infect. Dis. 14, 716-719 (2008). (Pubitemid 351838633)
173. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359, 2619-2620 (2008).
174. Noedl H. Artemisinin resistance: how can we find it? Trends Parasitol. 21, 404-405 (2005). (Pubitemid 41116714)
175. White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proc. Biol. Sci. 270, 545-554 (2003). (Pubitemid 36308233)
176. Rathod PK, McErlean T, Lee PC. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 94, 9389-9393 (1997).
177. Yeung S, Van Damme W, Socheat D, White NJ, Mills A. Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malaria J. 7, 96 (2008).
178. Butler D. Malaria drug-makers ignore WHO ban. Nature 460, 310-311 (2009).
179. Dondorp AM, Newton PN, Mayxay M et al. Fake antimalarials in southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop. Med. Int. Health 9, 1241-1246 (2004). (Pubitemid 40037159)
180. Newton PN, Fernandez FM, Plancon A et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in south east Asia. PLoS Med. 5, e32 (2008).
181. Keoluangkhot V, Green MD, Nyadong L, Fernandez FM, Mayxay M, Newton PN. Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether. Am. J. Trop. Med. Hyg. 78, 552-555 (2008). (Pubitemid 351845155)
182. Su XZ, Wootton JC. Genetic mapping in the human malaria parasite Plasmodium falciparum. Mol. Microbiol. 53, 1573-1582 (2004).
183. Fidock DA, Nomura T, Talley AK et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6, 861-871 (2000).
184. Su X, Hayton K, Wellems TE. Genetic linkage and association analyses for trait mapping in Plasmodium falciparum. Nat. Rev. Genet. 8, 497-506 (2007). (Pubitemid 46955213)
185. Anderson TJ, Roper C. The origins and spread of antimalarial drug resistance: lessons for policy makers. Acta Trop. 94, 269-280 (2005). (Pubitemid 40720332)
186. Wootton JC, Feng X, Ferdig MT et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418, 320-323 (2002). (Pubitemid 34790681)
187. Nair S, Williams JT, Brockman A et al. A selective sweep driven by pyrimethamine treatment in southeast Asian malaria parasites. Mol. Biol. Evol. 20, 1526-1536 (2003). (Pubitemid 37082588)
188. Mu J, Awadalla P, Duan J et al. Genomewide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat. Genet. 39, 126-130 (2007). (Pubitemid 46026512)
189. Jeffares DC, Pain A, Berry A et al. Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nat. Genet. 39, 120-125 (2007). (Pubitemid 46026511)
190. Volkman SK, Sabeti PC, DeCaprio D et al. A genome-wide map of diversity in Plasmodium falciparum. Nat. Genet. 39, 113-119 (2007).
191. Kidgell C, Volkman SK, Daily J et al. A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog. 2, e57 (2006).
192. Jiang H, Yi M, Mu J et al. Detection of genome-wide polymorphisms in the AT-rich Plasmodium falciparum genome using a high-density microarray. BMC Genomics 9, 398 (2008).
193. Neafsey DE, Schaffner SF, Volkman SK et al. Genome-wide SNP genotyping highlights the role of natural selection in Plasmodium falciparum population divergence. Genome Biol. 9, R171 (2008).
194. Dharia NV, Sidhu AB, Cassera MB et al. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol. 10, R21 (2009).
195. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malaria J. 8, 89 (2009).
196. Sibley CH, Barnes KI, Watkins WM, Plowe CV. A network to monitor antimalarial drug resistance: a plan for moving forward. Trends Parasitol. 24, 43-48 (2008).
197. Websites 201 WHO Global Malaria Program. 2008 World Malaria Report http://apps.who.int/malaria/wmr2008/
198. Roll Back Malaria. The Global Malaria action Plan: For a Malaria Free World www.rollbackmalaria.org/gmap/index.html
199. Guidelines for the Treatment of Malaria. WHO (2006) http://apps.who.int/ malaria/docs/TreatmentGuidelines2006.pdf